Tissue Regenix Group plc
TRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £53,000 | £46,620 | £48,035 | £50,918 |
| - Cash | £1,870 | £4,650 | £4,946 | £5,692 |
| + Debt | £10,465 | £9,395 | £9,608 | £7,947 |
| Enterprise Value | £61,595 | £51,365 | £52,697 | £53,173 |
| Revenue | £28,646 | £29,493 | £24,476 | £19,746 |
| % Growth | -2.9% | 20.5% | 24% | – |
| Gross Profit | £13,621 | £14,040 | £9,140 | £5,632 |
| % Margin | 47.5% | 47.6% | 37.3% | 28.5% |
| EBITDA | £1,364 | £446 | -£1,039 | -£3,035 |
| % Margin | 4.8% | 1.5% | -4.2% | -15.4% |
| Net Income | -£713 | -£1,713 | -£2,695 | -£4,792 |
| % Margin | -2.5% | -5.8% | -11% | -24.3% |
| EPS Diluted | -0.01 | -0.024 | -0.031 | -0.068 |
| % Growth | 58.4% | 21.9% | 54.3% | – |
| Operating Cash Flow | -£1,635 | £1,040 | -£1,409 | -£2,445 |
| Capital Expenditures | -£4,069 | -£863 | -£885 | -£1,488 |
| Free Cash Flow | -£5,704 | £177 | -£2,294 | -£3,934 |